TITLE

An implantable cardioverter-defibrillator but not amiodarone reduced risk for death in congestive heart failure

AUTHOR(S)
Corsello, Andrew
PUB. DATE
July 2005
SOURCE
ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study related to an implantable cardioverter-defibrillator for congestive heart failure. 70% of patients had New York Heart Association class II congestive heart failure (CHF) and 30% had class III CHF. 188 patients from the amiodarone and placebo groups crossed over to some form of implantable cardioverter-defibrillator (ICD) therapy. 259 patients in the ICD group received shocks from their device for any cause. Fewer patients who received ICD died from any cause than did those who received placebo. The Sudden Cardiac Death (SCD)-Heart Failure Trial (HeFT) trial provides evidence for prophylactic use of ICDs. The historical importance of SCD-HeFT and its effect on clinical practice must account for the trial's immediate influence on Medicare guidelines.
ACCESSION #
18053689

 

Related Articles

  • Post-ATHENA and beyond. Naccarelli, Gerald V. // Journal of Interventional Cardiac Electrophysiology;Jun2011, Vol. 31 Issue 1, p55 

    Dronedarone, an amiodarone analog, was developed to be a safer alternative to amiodarone. Dronedarone is useful in suppressing atrial fibrillation/flutter and controlling the ventricular response. Dronedarone reduced cardiovascular hospitalization in the ATHENA trial (A placebo-controlled,...

  • Efficacy of Amiodarone for the Termination of Chronic Atrial Fibrillation and Maintenance of Normal Sinus Rhythm: A Prospective, Multicenter, Randomized, Controlled, Double Blind Trial. Galperin, Jorge; Elizari, Marcelo V.; Chiale, Pablo A.; Molina, Remberto Torres; Ledesman, Raúl; Seapin, Angel O.; Blanco, Manuel Vázquez // Journal of Cardiovascular Pharmacology & Therapeutics;Oct2001, Vol. 6 Issue 4, p341 

    The article assesses the efficacy and safety of amiodarone for restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation in a prospective, randomized, double blind trial. Ninety-five patients with chronic atrial fibrillation, lasting an average of 35.6 months were...

  • Oral Amiodarone for Recent-Onset Atrial Fibrillation. Sadovsky, Richard // American Family Physician;8/15/2000, Vol. 62 Issue 4, p869 

    Presents information on a study by K. Peuhkurinen and others that evaluated the efficacy of a single oral dose of amiodarone versus placebo in patients with recent-onset atrial fibrillation. Description of the study and its results; Conclusion that 30 to 50 mg per kg of oral amiodarone is...

  • Dronedarone. Hoy, Sheridan M.; Keam, Susan J. // Drugs;2009, Vol. 69 Issue 12, p1647 

    â–´ Oral dronedarone is a non-iodinated benzofurane derivative structurally related to amiodarone. Although it is considered a class III antiarrhythmic agent like amiodarone, it demonstrates multiclass electrophysiological activity. â–´ Data from the ATHENA study demonstrated that...

  • Influence of the Placebo Effect upon the Healing Process. Squire, Carol // Positive Health;Apr2002, Issue 75, p27 

    Focuses on the influence of placebo effect in the healing process. Dependence of allopathic medicine to the placebo response; Assumption on the therapeutic effects of the placebo; Belief of the patient to the effectivity of a placebo.

  • Ethical questions over clinical use of placebo.  // Australian Journal of Pharmacy;May2009, Vol. 90 Issue 1068, p79 

    The article highlights some ethical questions over the clinical use of placebo treatments.

  • Placebo Therapy and the Law: Prescribe with Care*. Kapp, Marshall B. // American Journal of Law & Medicine;Winter83, Vol. 8 Issue 4, p371 

    The use of placebos by physicians for therapeutic purposes is a common part of clinical medical practice. This Article examines the legal and ethical ramifications of placebo prescription. In particular, ethical concerns are related to substantive legal theories that may be advanced to attack or...

  • No evidence that placebos have powerful clinical effects, study says. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);06/02/2001, Vol. 322 Issue 7298, p1325 

    Reports that treatment with placebo shows no evidence of having powerful clinical effects, according a study conducted at the University of Copenhagen. Reservations by many physicians toward the clinical use of placebos; Details of the study, which tested primarily the clinical effects of...

  • EMA's reflection on placebo does not reflect patients' interests. Bertele', Vittorio; Banzi, Rita; Gluud, Christian; Garattini, Silvio // European Journal of Clinical Pharmacology;May2012, Vol. 68 Issue 5, p877 

    In this article the authors discuss the European Medicine Agency's proposed policy on the extended use of placebo in research trials which evaluate pharmaceuticals. They are critical of the policy and suggest that is not in the best interest of patients and only serve to benefit drug...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics